Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma - Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00626704

Contacts


Contact: Amgen Call Center	866-572-6436

Locations


United States, Arizona
	Research Site	Recruiting
	Tucson, Arizona, United States

United States, California
	Research Site	Recruiting
	Duarte, California, United States
	Research Site	Recruiting
	Santa Monica, California, United States
	Research Site	Recruiting
	Stanford, California, United States
	Research Site	Recruiting
	Los Angelas, California, United States

United States, Illinois
	Research Site	Recruiting
	Evanston, Illinois, United States
	Research Site	Recruiting
	Chicago, Illinois, United States

United States, Maryland
	Research Site	Recruiting
	Baltimore, Maryland, United States

United States, Massachusetts
	Research Site	Recruiting
	Boston, Massachusetts, United States

United States, Minnesota
	Research Site	Recruiting
	Rochester, Minnesota, United States

United States, Oregon
	Research Site	Recruiting
	Portland, Oregon, United States

United States, Pennsylvania
	Research Site	Recruiting
	Radnor, Pennsylvania, United States
	Research Site	Recruiting
	Philadelphia, Pennsylvania, United States

United States, Tennessee
	Research Site	Recruiting
	Nashville, Tennessee, United States

Austria
	Research Site	Recruiting
	Wien, Austria

Belgium
	Research Site	Recruiting
	Brussel, Belgium
	Research Site	Recruiting
	Leuven, Belgium

France
	Research Site	Recruiting
	Villejuif, France
	Research Site	Recruiting
	Lyon, France
	Research Site	Recruiting
	Marseille, France

Netherlands
	Research Site	Recruiting
	Leiden, Netherlands
	Research Site	Recruiting
	Groningen, Netherlands

Sponsors and Collaborators

Amgen

Investigators


Study Director:	MD	Amgen